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1. Introduction 
Diabetes mellitus is characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin 
action, or both (Bennett & Knowler, 2005). The pathophysiology of type 2 diabetes mellitus 
(T2DM) includes three mechanisms: insulin deficiency due to insufficient pancreatic insulin 
production, excessive hepatic glucose release and insulinresistance in peripheral tissues and 
liver (Gurber, 2010). 
Usually, T2DM is associated with a cluster of cardiovascular and metabolic risks including 
obesity (especially abdominal obesity), decreased levels of high-density lipoprotein 
cholesterol (HDL), high levels of triglycerides, elevated blood pressure and silent 
inflammation and diabetes itself is considered to be a cardiovascular disease risk equivalent 
(Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology 
and the European Society for the Study of Diabetes, 2007). Taking into account the fact that 
T2DM is associated with obesity and excess fat accumulation may be the main cause of 
T2DM, one can evaluate the role of the endocannabinoid system (ECS) assessing (1) its role 
in the pathogeny of obesity and (2) the role of ECS on hyperglycemia; this last part can be 
split in (a) the implication of ECS on insulin resistance and (b) its effects on insulin release. 
2. The endocannabinoid system 
ECS is a very important physiological system involved in appetite stimulation, food intake 
and energy balance. Besides its metabolic functions, the ECS has also implications upon 
individual behavior, regarding preferences for sweets or fats, different substances abuses 
etc. 
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2.1 The endocannabinoid system – a historical perspective 
The history of the discovery of the endocannabinoid system is connected to the history of 
the human use of the cannabis. A special note is to be mentioned: at first there were 
discovered the exogenous substances that activate this system and then the receptors and 
finally the endogenous ligands of this system were described. The first evidence about 
human use of the plant Cannabis sativa comes from fragments of pottery from China almost 
10,000 years BC. These fragments appear to have some imprints of a plant that is considered 
to be hemp. Other proofs come from the cloths found in the Chinese burial chambers of the 
Chou dynasty (1122-265 BC). Therefore, the first use of cannabis appears to be for the 
manufacture of cloths, ropes and nets. The first description of the therapeutical effect of 
cannabis are from the Chinese pharmacopoeia Pen-ts’ao, ca. 1-2 century AD (Iversen, 2000). 
Nevertheless, it was only in 1964 when Gaoni and Mechoulam described the structure of 
delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance found in the 
cannabis plant (Howlett et al., 2004).  
The next step was the identification of specific sites for the action of Δ9-THC. In 1990, 
Matsuda et al. cloned the CB1 receptor, the main receptor for THC binding (Di Marzo, 2006). 
It was obvious that human body did not create cell receptors for exogenous substances only, 
therefore the endogenous ones had to be found. In 1992, Mechoulam and Pertwee 
discovered the first CB1 receptor agonist, anandamide, and they proved its THC-like 
functions. In 1993, Munro et al. cloned the CB2 receptor and two years later Mechoulam et 
al. and Waku et al. independently identified the second endogenous agonist of the 
cannabinoid receptors, 2-arachidonoyglycerol (2-AG). In the same year, Vicenzo di Marzo 
named these endogenous substances “endocannabinoids”, after the name given to 
endorphins and the name given to the entire system derived from here (Di Marzo, 2006).  
2.2 The structure of the endocannabinoid system 
ECS is composed of cannabinoid receptors CB1 and CB2, their endogenous ligands and the 
enzymes which mediate endogenous ligands’ biosynthesis and degradation (Lutz, 2002).  
2.2.1 The cannabinoid receptors 
There were identified two types of cannabinoid receptors until now. CNR1 represents the 
gene coding CB1 and it is localized at 6q14-q15 level. There is a significant similitude 
between the human CB1 and the one identified in rats or in mice and CB1 receptors were 
cloned in other species including fish and invertebrates. This receptor has 472 aminoacids 
and it is a G-protein coupled receptor with seven trans-membrane domains (Demuth & 
Molleman, 2006).  
CB1 receptors are expressed mainly in the brain, but also in other organs involved in 
energetic homeostasis: adipose tissue, liver, gastrointestinal tract, pancreas and skeletal 
muscle. There are several endogenous agonists of the cannabinoid receptors, anandamide 
(N-arachidonylethanolamine) and 2-arachidonoylglycerol (2-AG) being the two main 
important molecules (Demuth & Molleman, 2006). 
ECS is considered to link emotional response to stress with appetite and energy balance and 
it functions like an after stress recovery system which remains inactive in repose physiologic 
conditions. Activation of the central CB1 receptors is believed to modulate satiety and 
increase sensitivity to rewarding stimuli, including food (Eggan & Lewis, 2007). On the 
other hand, activation of CB1 receptors in the adipose tissue and in the liver can regulate 
metabolism and lipids storage (Jbilo et al., 2005). 
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The gene of the CB2 receptor is located on gene 1 at p36.11 level and it codes for a protein 
with 360 aminoacids. It is involved mainly in immunomodulation and its polymorphisms 
have been associated with autoimmune diseases (Sipe et al., 2005) but also with 
osteoporosis. 
Beside the two cannabinoid receptors, there are other possible targets for the cannabinoids: 
vanilloid receptors (transient receptor potential vanilloid type 1 – TRPV1), subtypes of CB1 
receptor, CB2-like receptors and possibly other non-CB1, non-CB2, non-TRPV1 receptors 
that can interact with the cannabinoids (Pertwee, 2005). 
2.2.2 The endocannabinoids and the cannabinoid receptor agonists 
After the discovery of the two types of cannabinoid receptors the subsequent research 
focused on the isolation of the main endogenous substances that interact with these 
substrates. In 1993, anandamide was discovered followed soon after by the isolation of the 
2-arachidonoylglycerol (2-AG) the endogenous compound with the most important 
cannabinoid receptor agonist activity (Lutz, 2002). After their isolation, it was noticed that 
the two substances were synthesized from the cell membrane-derived phospholipids and 
due to their lipophilic structure (Fig. 1), they are not needed to be stored in vesicles like 
other mediators. Anandamide has many biological in vivo and in vitro functions such as the 
activation numerous kinases like p38 mitogen-activated protein kinaze (p38 MAPK), c-Jun 
N-terminal kinase (JNK), protein kinase B, the stimulation of arachidonic acid release, 
appetite stimulation, memory inhibition, pain modulation, vasodilatation, blood pressure 
decrease and neuroprotection (Onaivi et al., 2005). 
 
 
Fig. 1. The structure of anandamide and 2-AG (adapted from Doyle, 2011) 
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Like anandamide, 2-AG has been found in various concentrations in the brain depending on 
the studied area, age, physiological and pathological conditions. 2-AG has a reduced 
binding activity compared to anandamide but it acts on both cannabinoid receptors and 
only on them. This is why some consider it as the only endogenous agonist of the ECS.  
Among the two substances, other products have been described as acting on the 
cannabinoid receptors. Oleamide, noladin ether (2-arachidonyl glyceryl ether), virodhamine 
and N-arachidonoyl-dopamine (NADA) can bind to one of the cannabinoid receptors. Their 
role in the physiology and physiopathology of the ECS has to be determined. 
2.2.3 The metabolism of the endocannabinoids 
The metabolic pathways of the two best described substances have many common features. 
Both compounds derive from the enzymatic hydrolysis of the products derived from the 
membrane phospholipids. Both substances are released and then taken back into the cell by 
diffusion and they are inactivated by intracellular hydrolysis. There are also some 
differences between the metabolic pathways of the two substances and this explains why the 
levels of these substances can vary depending on different physiological conditions 
(Pertwee, 2005). 
The life cycle of the endogenous cannabinoids is different from the one of the other 
endogenous ligands. Neither anandamide, nor 2-AG is held in vesicles, but they are 
synthesized “on demand” following the Ca2+ influx that determines the activation of the Ca2+-
dependent biosynthetic enzymes (Di Marzo et al., 1998). It was shown that endocannabinoids 
are retrograde signaling molecules that suppress GABA release from presynaptic terminals 
following depolarization of a hippocampal CA1 pyramidal neuron. This process is known as 
depolarization-induced suppression of inhibition (DSI) (Wilson & Nicoll, 2001). The synthesis 
of endocannabinoids is not well understood. The enzymes that mediate this process are still 
being characterized and it is not possible to localize it to a particular subcellular compartment. 
Some studies indicate that the endocannabinoids are released from neuronal somata and 
dendrites (Egertova et al., 1998). Soon after their synthesis in the postsynaptic cell, the 
endogenous cannabinoids are secreted by simple diffusion or passive (energy-independent) 
carrier proteins may be required. Afterwards, they bind within the binding site crevice formed 
by the seven transmembrane helices of CB1 receptor of the presynaptic neuron (Fig. 2). The 
subsequent activation of CB1 by endocannabinoids results in the inhibition of Ca2+ channels in 
the presynaptic cell. Because the release of cationic neurotransmitters from vesicles (in the 
presynaptic cell) is Ca2+-dependent, activation of CB1 results in the suppression of 
neurotransmitter release (Onaivi et al., 2005). 
Little is known also about the subsequent events following receptor interaction. It has been 
proposed that endocannabinoids are released into the extracellular space and then 
transported by a specific transport protein on both neurons and glia that mediate 
endocannabinoid uptake (Piomelli et al., 1998). It has also been shown that an antagonist of 
this transporter, AM404, potentiates the effect of exogenous anadamide on cultured 
neurons. After being transported into the cell, anadamide is subsequently broken down into 
arachidonic acid and ethanolamine by a membrane-bound enzyme called fatty acid amide 
hydrolase (FAAH) (Di Marzo et al., 1998; Piomelli et al., 1998) that is localized to the 
endoplasmic reticulum (Fig. 3). An alternative mechanism proposed by Deutsch et al. is that 
anandamide uptake after receptor interaction is a process of simple diffusion (Glaser et al., 
2003). The same authors indicated that transport inhibitors such as AM404 are actually 
inhibitors of FAAH in vitro. The mechanism of action for 2-AG appears to be similar. 
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Fig. 2. The mechanism of action of anandamide 
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Fig. 3. The uptake and degradation of anandamide 
2.2.4 The biology of cannabinoid signaling 
Retrograde synaptic signaling is considered a fundamental feature of the nervous system 
and endocannabinoids are one of the classes of retrograde messengers involved in the 
regulation of synaptic transmission. Thus, endocannabinoids mediate the rapid retrograde 
suppression of both excitatory and inhibitory synapses. Functionally, endocannabinoids are 
released from depolarized postsynaptic neurons in a calcium-dependent manner and act 
retrogradely onto presynaptic CB receptors to suppress neurotransmitter release. 
CB1 and CB2 receptors are coupled with G protein, negatively to adenylate cyclase and 
positively to mitogen-activated PK. CB1R couples to the G protein signal transduction 
pathways in presynaptic nerve terminals and transduces the cannabinoid stimulation of 
MAP kinase and the inhibition of adenylate cyclase, thereby attenuating the production of 
cyclic AMP. CB1Rs are also coupled to ion channels through G proteins, positively to A-type 
and inwardly rectifying potassium channels, and negatively to N-type and P/Q-type 
calcium channels and to D-type potassium channels (Howlett and Mukhopadhyay, 2000). 
The quantity of cAMP decreases and cAMP-dependent PK (PKA) is inhibited by CB1R 
activation. In the absence of cannabinoids, PKA phosphorylates the potassium channel 
protein and exerts decreased outward potassium current. In the presence of cannabinoids 
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the phosphorylation of the channel by PKA is reduced, which increases the outward 
potassium current. Moreover, cannabinoids can close sodium channels, but whether or not 
this effect is receptor mediated has yet to be established. Other cellular responses triggered 
with CB1 receptor activation include other PK pathways such as the p38 MAKP, JUN N-
terminal kinase, (JNK), focal adhesion kinase (FAK), and phosphoinositide-3 kinase (Akt) 
signaling, which might mediate effects on apoptosis (Molina-Holgado et al., 2002). 
Acting on ion channels, the endocannabinoids mediate the rapid retrograde suppression of 
both excitatory and inhibitory synapses. Functionally, they are released from depolarized 
postsynaptic neurons in a calcium-dependent manner and act retrogradely onto presynaptic 
CBRs to suppress neurotransmitter release. 
3. The role of ECS in obesity 
The pathophysiological role of ECS has been documented on numerous studies involving 
animal models and also humans. Some of the animals used in the studies developed obesity 
as a result of leptin gene or leptin receptor gene mutations and others presented diet-
induced obesity (DIO). These are the two main representative types of obesity: genetic or 
diet-induced.  
It has been described that ECS plays an important role in the regulation o food intake by 
homeostatic and non-homeostatic (or hedonic) energy regulation pathways (Matias et al., 
2008).  
It was noticed that hypothalamic levels of endocannabinoids were increased in all models of 
leptin deficiency or defective leptin receptors signaling. This study proved the negative 
regulation of endocannabinoids by leptin. Moreover, leptin treatment for these mice leads to 
an important reduction of endocannabinoids levels (Engeli, 2008). It was also proved that 
hypothalamic endocannabinoid levels are decreased after systemic leptin administration in 
rats, and increased in rodent models of congenital hyperphagia and obesity, such as db ⁄ db 
mice and Zucker rats, where leptin signalling is defective, as well as in ob ⁄ ob mice, where 
leptin biosynthesis is defective and exogenous leptin can restore the normal (low) levels of 
endocannabinoids. 
DIO also has an impact on ECS regulation. There were found increased levels of 
anandamide after feeding piglets a diet enriched in long-chain polyunsaturated fatty acids 
(LC-PUFA) like arachidonic acid and docosahexaenoic acid (DHA). These models also 
presented CB1 receptor downregulation in hypothalamus and the authors explained it as a 
result of increased levels of anandamide and 2-AG in extra-hypothalamic regions. Lower 
CB1 density was correlated with cumulative energy intake from the palatable, fat-enriched 
diet. In contrast, a fish-oil diet was associated with reduced 2-AG levels in the brain (Engeli, 
2008). 
After food deprivation, endocannabinoids act on CB1 receptors stimulating the central 
orexigenic system in the hypothalamus, therefore, controlling the homeostatic regulation of 
food imbalance (Di Marzo et al., 2001). Besides that, ECS may stimulate food intake by 
reinforcing the motivational processes involving the nucleus accumbens (Matias et al., 2008). 
Endocannabinoids, directly injected in the hypothalamus or the nucleus accumbens, can 
induce food-intake in satiated animals (Cota et al., 2006). Therefore, it appears that the ECS 
participates in the orexigenic hypothalamic network regulated by leptin. Moreover, CB1 
receptors are distributed in the hypothalamus in a way suggesting that they regulate 
directly the expression of orexigenic signals such as agouti-related protein (AGRP), orexins 
and melanocyte-concentrating hormone (MCH) or anorexic signals such as those produced 
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from pro-opiomelanocortin (POMC) and the cocaine-and amphetamine-regulated transcript 
(CART) (Cota et al., 2003). 
The ECS is implicated in adipose tissue homeostasis also directly via CB1 receptors located 
in adipocytes. Cota et al. were the first that suggested the implication of ECS in energy 
balance regulation by acting directly on peripheral CB1 receptors (Cota et al., 2003). Many 
researchers started their work to discover the peripheral mode of action of the ECS as a 
system that reduces energy expenditure and directs energy balance towards energy storage 
into the adipose tissue. Other organs involved in the process of energy storage are the liver, 
the skeletal muscle and the pancreas. It is well known that dietary triglycerides are 
transported to the liver from the intestine via chylomicrons. In addition, hepatic triglyceride 
synthesis from fatty acids and glycerol takes place under the influence of insulin produced 
by the pancreas in the postprandial state. Triglycerides are then secreted into blood as very 
low density lipoproteins (VLDL) that go either to the adipose tissue to be store as re-
esterified triglycerides, or are metabolized into fatty acids that will be used as energy source 
after mitochondrial ǃ-oxidation. Another major energy source in the body is represented by 
the oxidisable glucose in the skeletal muscle. The muscle will contribute to energy balance 
also by regulating the circulating levels of nutrients, and in particular of glucose, which can 
also be transformed into fatty acid precursors in the adipose tissue and the liver.  
Several studies demonstrated the presence of endocannabinoid receptors in both animal and 
human adipose tissue. CB1 receptors are present in white adipose tissue and coupled to 
stimulation of lipoprotein lipase. These findings suggested that the ECS tonically contributes 
to fat accumulation, independently from the amount of food ingested and by acting directly 
on the adipose tissue. Studies carried out in the mouse 3T3 adipocyte cell lines showed that 
the blockade of CB1 receptors arrests adipocyte proliferation (Gary-Bobo et al., 2006), 
suggesting that endocannabinoids might stimulate proliferation. Moreover the formation of 
endocannabinoids precedes pre-adipocyte differentiation into mature adipocytes and  
chronic stimulation of CB1 receptors during adipocyte differentiation accelerates the 
appearance of an early marker of differentiation, peroxisome proliferator- activated 
receptor-Ǆ (PPAR-Ǆ), while inducing accumulation of lipid droplets (Matias et al., 2006). 
Cota et al. showed that CB1 receptor null mice exhibited significantly lower amounts of fat 
mass and higher amount of lean mass than wild-type mice even when fed with the same 
amount of food (Matias et al., 2008). Also, CB1 receptor protein expression increased with 
increasing adipocyte size and adiposity while exercise training inhibited these receptors and 
the peroxisome proliferators-activated receptor-ǅ (PPARǅ). PPARǅ tonically inhibits the 
expression of CB1 in a mouse clonal adipocyte cell line (Yan et al., 2007). When speaking of 
human studies, one study showed increased levels of anandamide and 2-AG in the plasma 
of menopausal obese women when compared with lean women of the same age (Engeli, 
2008). Anandamide and 2-AG were increased in plasma of obese subjects with diabetes too. 
In a study that compared lean and obese men and women with either subcutaneous or 
visceral adipose tissue accumulation, 2-AG plasma levels were clearly correlated with 
visceral adipose tissue mass and the group with subcutaneous adipose tissue did not differ 
from the lean control group with regard to 2-AG plasma concentration (Bluher et al., 2006). 
The same study indicated that women had higher anandamide plasma levels than men, but 
no relationship with obesity or body fat distribution was found. Another study to support 
these findings was performed in 62 men and the subjects in the highest tertile of 2-AG levels 
presented with markedly increased visceral adipose tissue mass despite having almost the 
same body mass index as those in the lower two tertiles of plasma 2-AG. On the other hand, 
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anandamide was negatively correlated with visceral fat mass (Cote et al., 2007). Both studies 
showed that increased plasma 2-AG correlates with markers of metabolic syndrome (such as 
free fatty acids, triglycerides, HDL cholesterol, adiponectin), and is associated with 
decreased insulin sensitivity and enhanced glucose and insulin responses during an oral 
glucose load.  
While the role of the brown adipose tissue in humans is less clear, it is known that it 
importantly contributes to thermogenesis and energy expenditure in small mammals. CB1 
receptors are also present in mouse brown adipocytes (Perwitz et al., 2006) and the 
endocannabinoids might, therefore, regulate thermogenesis in this tissue. It has been 
demonstrated that CB1 inhibits the uncoupling protein-1 (UCP-1), a thermogenic, 
mitochondrial, proton translocating membrane protein (Perwitz et al., 2006). 
Another mechanism may involve adiponectin, which is a cytokine that reduces the 
circulating levels of free fatty acids by inhibiting lipid storage stimulating fatty acid 
oxidation. It was proved that stimulation of CB1 receptors inhibits adiponectin expression in 
mature adipocyte while their blockade was associated with increased adiponectin 
expression (Matias et al., 2008). It is possible for CB1 receptors to induce lipogenesis by 
inhibition of cAMP formation. Matias et al. (Matias et al. 2006) found that, in mature 
adipocytes, a CB1 receptor agonist inhibited cAMP formation in a way that was significantly 
attenuated by CB1 receptor antagonists but not by a CB2 receptor antagonist. Inhibition of 
cAMP and, subsequently, protein kinase A (PKA) might stimulate lipogenesis by inhibiting 
the AMP-activated protein kinase (AMPK). This enzyme is stimulated by PKA-mediated 
phosphorylation and plays a key role in energy metabolism because it reduces fatty acid 
synthesis and stimulates fatty acid ǃ-oxidation in several tissues. Interestingly, other studies 
demonstrated that Δ9- THC decreases AMPK phosphorylation both in subcutaneous and, 
particularly, visceral adipose tissue (Kola et al., 2005). Because adiponectin stimulates 
AMPK activity, the CB1-mediated inhibition of adiponectin expression in adipocytes might 
reinforce this effect (Matias et al. 2006). 
Another way for ECS-enhanced lipogenesis in adipocytes might be through their ability to 
stimulate glucose uptake by these cells via the enhancement of both basal and insulin-
induced translocation to the plasma membrane of the glucose transporter 4 (GLUT4) 
(Gasperi et al., 2007; Pagano et al., 2007). In mouse adipocytes this effect seems to be 
mediated by CB1-induced stimulation of nitric oxide synthesis (Gasperi et al., 2007), while in 
human adipocytes CB1 activates the phosphatidylinositol-3-kinase cascade (Pagano et al., 
2007). Increased glucose uptake and, subsequently, glycolysis might be the way for de novo 
fatty acid biosynthesis, and this effect might underlie part of the pro-lipogenetic effect of 
CB1 receptor agonists in these cells (Matias et al., 2008). 
A few studies tried to determine the effect of weight loss on ECS in obese subjects (Engeli et 
al., 2005, Engeli et al., 2008). Unfortunately, in all these studies, circulating anandamide and 
2-AG, CB1 and FAAH gene expression in subcutaneous abdominal adipose tissue, were not 
influenced by weight loss, although metabolic parameters such as fasting insulin and blood 
pressure were significantly decreased as surrogates of successful therapy. The authors 
explained that weight loss might not have been large or fast enough and that, probably with 
a more rigid protocol, an influence on the ECS might have been seen. If weight loss does not 
influence the ECS in obese subjects, an alternative hypothesis is that genetic modifications 
could be the cause of dysregulation of the ECS in obesity. 
There were several studies concerning the mutations of the CNR1 gene that encodes CB1 
receptor. Russo et al. analyzed two variants of exon 4 of CNR1, scanning the gene for 
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polymorphisms rs12720071 (3813A/G) and rs806368 (4895A/G), in a study carried out on a 
group of European men. The results indicated that allele 3813G was associated with the 
growth of abdominal circumference (AC), subscapular cutaneous skinfold and body mass 
index (BMI). There have been observed no associations between rs806368 polymorphism 
and the determined variables. The haplotype’s analysis consisted in the studying of 3 
frequent haplotypes: A3813A4895 (AA), A3813G4895 (AG) and G3813G4895 (GG), 
haplotype GG being associated with the increase of the abdominal circumference and 
subscapular cutaneous skinfold (Russo et al., 2007).  
The polymorphism rs1049353 (1422A/G) was associated in men with a significant increase 
of the abdominal circumference, waist to hip ratio and of adipose mass after the adjustment 
for age and BMI. Adipose mass percent was also associated with this polymorphism but the 
association disappeared after the adjustment for age and BMI (Peters et al., 2007). Another 
study carried out on Swedish and Danish subjects indicated that polymorphisms rs806381, 
rs2023239, rs6454674 and rs10485170 associated with an increased BMI (Benzinou et al., 
2008).  
 
 
Fig. 4. The role of ECS in energy balance (adapted after Matias et al., 2008). 
Muller et al. studied 8 polymorphisms in German children and adolescents: in region 5' 
(rs9353527, rs754387, rs6454676), in intron 2 (rs806379, rs1535255), exon 3 (rs2023239), intron 
3 (rs806370) and in coding region (rs1049353), but they couldn’t find any association with 
obesity (Muller et al., 2007). 
Probably the most important proofs, that ECS is involved in obesity, come from the studies 
using selective CB1 receptors antagonists such as Rimonabant, where a significant reduction 
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of body fat was noticed. The Rimonabant in Obesity (RIO) study indicated that 1 year 
treatment with selective CB1 receptor antagonist, rimonabant 20mg, significantly reduced 
weight and abdominal circumference compared with diet and lifestyle therapy alone (Di 
Marzo et al., 2008). The figure 4 describes the ways by which ECS controls the energy 
balance. 
4. The role of ECS in insulin sensitive organs 
Adipose tissue. It is well known that adipose tissue is, beside the major energy depot, a very 
important source of adipokines that play a major role in insulin sensitivity and glucose 
homeostasis and the role of the ECS in modulating the adipose tissue was already discussed. 
Adiponectin is one of the adipokines involved in free fatty acid oxidation and 
hyperglycemia improvement (Kadowaki et al., 2006). It was already mentioned that 
overactivation of ECS is associated with low adiponectin levels and dysregulation of the 
adipose tissue. 
Liver. Activation of CB1 receptors in mice leads to increased de novo fatty acid synthesis. 
One of the studies concerning the role of the ECS in the liver demonstrated, in rat 
hepatocytes, that anandamide inhibits acetyl-CoA-carboxylase activity leading to inhibition 
of de novo fatty acid synthesis. Furthermore, fatty acid oxidation was found to be increased 
since carnitine palmitoyltransferase-1 and the rate of ketogenesis from palmitate were 
stimulated by anandamde. Both effects on fatty acid synthesis and oxidation were prevented 
by an inhibitor of the anandamide enzymatic hydrolysis via FAAH (Guzman et al., 1995). 
This study, that presents the role of arachidonic acid originating from anandamide in 
stimulating the oxidation of fatty acids and inhibiting their synthesis, is of a great 
importance.  
Activation of CB1 receptors in the liver also affects fatty acid homeostasis: CB1 receptors are 
expressed in hepatocytes, mainly around the centrilobular vein, and CB1-⁄- mice exhibit 
lower expression of the important transcription factor SREBP-1c that is implicated in the 
regulation of fatty acid synthesis (Osei-Hyiaman et al., 2005). Activation of CB1 receptors in 
the liver enhances the expression of SREBP-1c and of its targets. These effects may explain 
the stimulatory effect of a CB1 receptor agonist on fatty acid synthesis and lipogenesis in 
these cells. Measurement of the fatty acids production in the liver after pretreatment of mice 
with a cannabinoid receptor agonist indicated a twofold increase of fatty acid synthesis 
(Osei-Hyiaman et al., 2005). An increase of fatty acids synthesis was also noticed in 
hepatocytes isolated from mice and treated with tge same CB1 agonist. The increase in fatty 
acids synthesis was found neither in the liver nor in isolated hepatocytes from mice 
pretreated with rimonabant or CB1 receptor knockout (CB1-⁄-) mice. These mechanisms 
explain the lipogenetic action of CB1 receptors in these cells.  
A great observation was that CB1-⁄- mice, unlike their wild-type littermates, do not develop 
hepatic steatosis after several weeks of a high-fat diet, a condition that leads to up-
regulation of both hepatic anandamide and CB1 expression levels and down-regulation of 
FAAH.  
In conclusion, the possible mechanism explaining the role of the ECS in the liver is the 
following: under normal energy homeostatic conditions, the low levels of CB1 receptors and 
high levels of FAAH increase the arachidonic-acid-mediated stimulation of fatty acid 
oxidation by anandamide. After several weeks of a high-fat diet the reduction of FAAH 
activity and the enhancement of CB1 receptors favour instead anandamide and CB1-
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mediated hepatic lipogenesis (Matias et al., 2008). It is possible for the endocannabinoids to 
exert a function on glucose homeostasis in the liver also in healthy animals, because a CB1 
receptor blocker was proven to stimulate glycogenolysis in liver in lean normoglycemic rats 
(Herling et al., 2007).  
As it was mentioned, ECS might contribute o the development of diet induced obesity, 
which is found to be associated with an increase in the hepatic levels of the 
endocannabinoid anandamide and CB1-mediated fatty acid synthesis in mice (Nogueiras et 
al., 2008). 
Muscle. One of the evidences of the involvement of the ECS in energy expenditure at the 
level of the skeletal muscle came from the observation that blood anandamide levels were 
significantly elevated in runners and cyclists but not in sedentary controls following 1h of 
moderate intensity exercise (Sparling et al., 2003). Other studies indicated that CB1 receptor 
knockout mice had higher energy expenditure, probably due to the energy combustion 
produced by fat or carbohydrate oxidation. Recent studies demonstrated that administration 
of a CB1 receptor antagonist increased energy expenditure in rats. A study about the chronic 
administration of rimonabant showed enhanced glucose uptake and oxidation by the 
isolated soleus muscle of genetically obese mice (Liu et al., 2005). Moreover, another study 
indicated that the very low density of CB1 receptors in the mouse soleus muscle increases 
when the animals are kept on a high-fat diet (Pagotto et al., 2006). Another study that dealed 
with the effect of a CB1 receptor antagonist AM251 in an in vitro model of skeletal muscle, 
indicated that this one increases the expression of AMPKǂ1 and decreases that of the 
pyruvate dehydrogenase kinase-(PDK)4 (Cavuoto et al., 2007). More importantly, 
anandamide blocked only the effect of AM251 on the expression of AMPKǂ1, and not that 
on PDK4, suggesting that only the former effect, and the subsequent likely activation of 
lipolysis and fatty acid oxidation, of the CB1 receptor antagonist is CB1 receptor-mediated. 
PDK4 is known as an important inhibitor of the pyruvate dehydrogenase complex, which 
links glycolysis to ATP production and to the Krebs cycle and its inhibition by AM251 might 
stimulate glucose flux into the mitochondria and cause an increase of glucose oxidation in 
the muscle. The opposite is expected to occur with endocannabinoids (Cavuoto et al., 2007). 
In leptin-deficient mice that exhibit hyperglycemia and insulinresistance, treatment with 
selective CB1 receptors antagonists increased basal oxygen consumption and glucose uptake 
in isolated soleus muscle preparations (Liu et al., 2005). 
5. The ECS in the pancreas 
Several findings suggest that ECS in involved not only in glucose uptake but also in the 
control of insulin levels. In pancreatic islets from mice, it was noticed that CB1 receptors are 
mainly expressed in non-ǃ cells whereas CB2 are expressed in both ǃ and non-ǃ (Juan-Pico 
et al., 2006). There were seen differences between mice and rats, while in rats and humans 
both CB1 and CB2 receptors were noticed in both ǂ- and ǃ-cells (Matias et al., 2008; Di 
Marzo, 2008).  
Juan-Pico et al. (Juan-Pico et al., 2006) observed co-localization of CB1 receptors with 
glucagons predominantly but some co-staining with insulin was also noticed particularly in 
human islets. Nakata and Yada (Nakata & Yada, 2008) observed co-localization of CB1 
receptor with insulin in some but not all ǃ-cells in mouse islets. Another study of Starowicz 
et al. indicated that CB1 receptors are highly co-expressed with glucagon in both mice and 
rats with a wider distribution of the CB2R throughout more of the islet cell types (Starowicz 
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et al., 2008). On the other hand, Li et al. (Li et al., 2010a) showed co-expression of both CB1 
and CB2 receptors with insulin but not with glucagons expressing cells in the mouse. A 
possible explanation for all these contrasting results came from a recent publication that 
proved that many commercial CB1 receptor antibodies exhibit nonspecific interactions 
(Grimsey et al., 2008). 
There is evidence for the expression in the pancreatic islet of all the molecules requested for 
the synthesis and degradation of the endocannabinoids (Bermudez-Silva et al., 2008). In 
conditions of hyperglycemia, over-expression of biosynthetic endocannabinoid enzymes 
and low levels of degrading enzymes was noticed. 
In insulinoma cell lines from rats and also humans islets there were noticed increased levels 
of the endocannabinoids in response to glucose stimulation (Bermudez-Silva et al., 2008). It 
is known that ǃ-cells are depolarized and they release of calcium in response to glucose-
stimulated insulin release. Therefore, the increased calcium levels stimulate their synthesis 
in the ǃ-cells. 
Two studies (Juan-Pico et al., 2006; Nakata & Yada, 2008) observed a decrease in the 
amplitude of glucose-induced calcium oscillations in mouse islets in response to treatment 
with 2-AG (10mmol/l) and anandamide (1mmol/l). A decrease in calcium oscillations 
would be expected to adversely affect insulin secretion. Juan-Pico et al. noticed a 30% 
reduction in static insulin secretion by the endocannabinoids and Nakata and Yada 
observed a concentration-dependent inhibition of insulin release by AEA (1–10mmol/l) in 
mouse islets. Moreover, Nakata and Yada also noticed a decrease in glucose-induced 
calcium oscillations and insulin secretion in response to a more specific CB1 receptor 
agonist. The same authors also showed that a general CB1/CB2 receptor agonist and a 
specific CB1 receptor agonist, arachidonyl-2-chloroethylamide (ACEA) (100 nmol/l) 
significantly decreased insulin secretion from mouse islets. All these initial in-vitro 
experiments in rodents indicate that endocannabinoids and CB1 receptor agonists have 
deleterious effects on insulin secretion.  
Li et al. (Li et al., 2010a,b) showed that treatment with ACEA (10mmol/l) decreased cAMP 
production in a mouse clonal ǃ-cell and mouse islets. However this same group showed a 
concurrent increase in calcium levels in, and insulin secretion from, mouse b-cells in 
response to these cannabinoid receptor agonists in the presence of glucose (Doyle, 2011).  
The apparent contradiction to the previous published results and to the fact that cAMP and 
calcium oscillations following glucose-stimulated insulin secretion are highly 
interdependent and amplify each other (Ni et al., 2011) was explained by the same author by 
stating that the stimulatory effect of cannabinoid receptor agonism on intracellular calcium 
levels overrides the inhibitory effect on cAMP production (Doyle, 2011). 
Because ECS appears to modulate glucose homeostasis in both glucose dependent insulin 
release and glucose uptake from tissues pathways, studies to evaluate the glucose 
homeostasis in vivo were performed. Systemic stimulation of CB1 receptors in lean 
normoglycemic rats determined slower blood glucose clearance while activation of CB2 
receptors improved glucose clearance (Matias et al., 2008).  
When anandamide or ACEA were administered acutely to Wistar rats prior to a glucose 
tolerance test, the rats developed severe glucose intolerance (Bermudez-Silva, 2006). The 
effect was reversed by the CB1 receptor antagonist AM251, suggesting direct effect on 
glucose tolerance through this receptor. In this study, the authors did not measure insulin 
secreted during the glucose tolerance test so it can not be estimated the direct effect on 
insulin secretion (Doyle, 2011). In another study, they examined glucose tolerance in 
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response to specific CB1 and CB2 receptors agonists and antagonists and they confirmed the 
specific effect of the CB1 receptor on glucose intolerance with CB2 receptor imparting a 
degree of glucose tolerance (Bermudez-Silva et al., 2008).  
Subchronic administration (18 days) of AM251 (6 mg/kg, interperitoneal) decreased 
circulating plasma glucose and increased glucose tolerance after a glucose load in ob/ob 
mice (Irwin et al., 2008). 
Other studies observed that CB1 stimulation increased insulin secretion. Interestingly, CB1 
agonists also enhanced glucagons release from human alpha cells and CB2 agonists reduce 
both insulin and glucagon release (Di Marzo, 2008). The possible explanation was that CB1 
receptors inhibit glucose expenditure by inhibiting insulin utilization in skeletal muscle but 
enhancing it in the adipose tissue for energy storage into fats (Matias et al. 2008). 
 
 
Fig. 5. The major mechanisms by which over-activation of ECS may lead to T2DM 
The major evidence that dysregulated ECS is involved in glucose homeostasis comes from 
the clinical studies using CB1 receptor antagonists treatment. The Rimonabant in Obesity 
(RIO) study indicated that 1 year treatment with selective CB1 receptor antagonist, 
rimonabant 20mg, significantly reduced weight and abdominal circumference compared 
with diet and lifestyle therapy alone. The RIO-Lipids trial showed that subjects with 
dyslipidaemia and body mass index between 27 and 40kg/m2 exhibited significant increase 
in HDL-cholesterol, reduction in plasma triacylglycerol and increase in plasma adiponectin 
levels. The RIO-Diabetes trial enrolled 1045 overweight/obese subjects with T2DM that 
received treatment with metformin or sulfonylurea treatment alone. The subjects receiving 
rimonabant showed significant body weight reduction improvement in glucose control. 
Approximately 50% of the improvements in HbA1c levels were independent of weight loss 
(Di Marzo, 2008). The results can be attributed in part to a reduction in insulin resistance in 
the liver, fat and skeletal muscle, and an increase in lipolysis and direct effects also on the 
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pancreatic ǃ-cell cannot be ruled out (Van Gaal et al., 2008). In October 2008, rimonabant 
was withdrawn from market in Europe and it was not approved for use in the USA due to 
the severe psychiatric side-effects including anxiety, depression, and suicidal ideation 
(Doyle, 2011). 
The main mechanisms explaining the implication of the ECS in the pathogeny of T2DM are 
represented in Figure 5. 
6. Future perspectives 
Unfortunately, the withdrawal of rimonabant, due to the psychiatric side affects, diminished 
the interest for investigating the role of ECS in the pathogeny of T2DM. 
But as previous studies and RIO trials indicated, the ECS has an important role in the 
pathogeny of T2DM and obesity proving the fact that it represents a physiological system 
implicated in energy storage, contributing together with other genes and systems at the 
“thrifty phenotype” that can lead to pathological conditions like T2DM and diabetes when 
over-activated.  
 
 
Fig. 6. The possible ways for targeting the ECS (adapted from Patti et al., 2010) 
Nevertheless, emerging evidence supported the idea that interrupting endocannabinoid 
action selectively only in peripheral tissues may be an approach to treat the metabolic 
consequences of obesity and related diseases, including type 2 diabetes, without causing the 
undesirable CNS effects that occurred with rimonabant. The studies of Tam and colleagues 
brought back the attention to the ECS (Tam et al., 2010). Tam et al. first developed a CB1 
antagonist (AM6545) that retained binding activity but could not penetrate the brain due to 
its reduced lipid solubility (Tam et al., 2010). Therefore, it could not block the CB1 receptors 
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in the CNS. Remarkably, acting only on peripheral CB1 receptors AM6545 reduced body 
weight and adiposity in mice with diet-induced obesity and also improved systemic 
metabolism, as indicated by reduced fasting glucose, improved glucose tolerance, reduced 
insulin and leptin levels, increased adiponectin levels, and reduced hepatic triglyceride 
content in mice with diet-induced obesity (Patti et al., 2010) (Figure 6). The potency of 
AM6545 was a bit smaller probably due to additional centrally mediated effects of 
rimonabant on food intake or metabolism. 
The discovery of the ECS represents a great step towards better understanding the 
pathogeny of obesity and T2DM. Due to its numerous interactions with other physiological 
systems, it remains an important target for the future treatments of T2DM and not only. In 
order to clearly elucidate the role of this system and for the development of peripheral 
selective, nonbrain penetrant, CB1 receptor antagonists, future studies are needed. 
7. Acknowledgements 
This study is part of research grant financed by the National University Research Council – 
MEDC - ANCS Grant, PN II - ID 711- No 234/01.10.2007. Project Director, Prof. Maria Mota. 
8. References 
Bennett, P.H. & Knowler W.C. (2005). Definition, Diagnosis, and Classification of Diabetes 
Mellitus and Glucose Homeostasis, In: Joslin’s Diabetes Mellitus. Kahn, C.R., (Ed.), 
pp. 331-340, Lippincott Williams & Wilkins, ISBN 978-078-1727-96-9, Boston, MA, 
USA 
Benzinou, M. et al. (2008). Endocannabinoid receptor 1 gene variations increase risk for 
obesity and modulate body mass index in European populations. Hum Mol Genet. 
Vol.17, No.13, pp. 1916-21 
Bermudez-Silva, F.J. et al. (2006). Activation of cannabinoid CB1 receptors induces glucose 
intolerance in rats. Eur J Pharmacol. No.531, pp. 282–284 
Bermudez-Silva, F.J. et al. (2008). Presence of functional cannabinoid receptors in human 
endocrine pancreas. Diabetologia. Vol.51, pp. 476–487 
Bluher M, et al. (2006). Dysregulation of the peripheral and adipose tissue endocannabinoid 
system in human abdominal obesity. Diabetes. No.55, pp.3053–3060 
Cavuoto, P,. et al. (2007). Effects of cannabinoid receptors on skeletal muscle oxidative 
pathways. Mol Cell Endocrinol. No.267, pp. 63–69 
Cota, D. et al. (2003). The endogenous cannabinoid system affects energy balance via central 
orexigenic drive and peripheral lipogenesis. J Clin Invest. No.112, pp. 423–431 
Cota, D. et al. (2006). Cannabinoids, opioids and eating behavior: the molecular face of 
hedonism? Brain Res Rev. No.51, pp. 85–107 
Cote, M. et al. (2007). Circulating endocannabinoid levels, abdominal adiposity and related 
cardiometabolic risk factors in obese men. Int J Obes No.31, pp. 692–699 
Demuth, D.G. & Molleman, A. (2006). Cannabinoid signaling. Life Sci, No.78, pp. 549-563 
Di Marzo, V. et al. (1998) . Endocannabinoids: endogenous cannabinoid receptor ligands 
with neuromodulatory action. Trends Neurosci, No.21, pp. 521–528 
Di Marzo, V. et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining 
food intake. Nature. No.410, pp. 822–825 
www.intechopen.com
 
The Role of the Endocannabinoid System in the Pathogeny of Type 2 Diabetes 
 
305 
Di Marzo, V. (2006) A brief history of cannabinoid and endocannabinoid pharmacology as 
inspired by the work of British scientists. Trends Pharmacol Sci, Vol.27, No.3, pp. 
134-40 
Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2 diabetes. 
Diabetologia. Vol.51, pp. 1356-1367 
Doyle, M.E. (April 2011). The role of the endocannabinoid system in islet biology. Curr Opin 
Endocrinol Diabetes Obes. Vol.18, No.2, pp. 153-158 
Egertova, M. et al. (1998). A new perspective on cannabinoid signalling: complementary 
localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R 
Soc Lond B Biol Sci. No.265, pp. 2081–2085 
Eggan, S.M. & Lewis, D.A. (2007). Immunocytochemical distribution of the cannabinoid CB1 
receptor in the primate neocortex: a regional and laminar analysis. Cereb. Cortex, 
Vol.17, No.1, pp. 175–191 
Engeli, S. et al. (2005). Activation of the peripheral endocannabinoid system in human 
obesity. Diabetes. No.54, pp. 2838–2843 
Engeli, S (2008). Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol. 
No.20, pp. 110–115 
Engeli, S. et al. (2008). Peripheral endocannabinoid system activity in patients treated with 
sibutramine. Obesity. Vol.16, No.5, pp. 1135-7 
Garber, A.J. (2010). Incretin-based therapies in the management of type 2 diabetes: rationale 
and reality in a managed care setting. Am J Manag Care, Vol.16, No.7 Suppl, pp. 
S187-94.  
Gary-Bobo, M. et al. (2006). The cannabinoid CB1 receptor antagonist rimonabant 
(SR141716) inhibits cell proliferation and increases markers of adipocyte aturation 
in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol. No.69, pp.471–478 
Gasperi, V. et al. (2007). Endocannabinoids in adipocytes during differentiation and their 
role in glucose uptake. Cell Mol Life Sci. No.64, pp. 219–229 
Glaser, S.T. et al. (2003) Evidence against the presence of an anandamide transporter. Proc 
Natl Acad Sci USA Vol.100, No.7, pp. 4269–74 
Grimsey, N.L. et al. (2008). Specific detection of CB1 receptors; cannabinoid CB1 receptor 
antibodies are not all created equal! J Neurosci Methods. No.171, pp. 78–86 
Guzman, M. et al. (1995). Effects of anandamide on hepatic fatty acid metabolism. Biochem 
Pharmacol. No.50, pp. 885–888 
Herling, A.W. et al. (2007). CB1 receptor antagonist AVE1625 affects primarily metabolic 
parameters independently of reduced food intake in Wistar rats. Am J Physiol 
Endocrinol Metab. No.293, pp. E826–E832 
Howlett, A.C. & Mukhopadhyay, S. (2000) Cellular signal transduction by anandamide and 
2-arachidonoylglycerol. Chem. Phys. Lipids. No.108, pp. 53–70 
Howlett, A.C. et al. (2004). Cannabinoid physiology and pharmacology: 30 years of 
progress. Neuropharmacology, No.47, pp. 345–358 
Irwin, N. et al. (2008). Antidiabetic effects of sub-chronic administration of the cannabinoid 
receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur J Pharmacol. 
No.581, pp. 226–233 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
306 
Iversen, L.L. (2000). The science of Marijuana. Oxford University Press, ISBN 0-19-513123-1, 
New York, USA 
Jbilo, O. et al. (2005). The CB1 receptor antagonist rimonabant reverses the diet induced 
obesity phenotype through the regulation of lipolysis and energy balance. FASEB J, 
Vol.19, No.11, pp. 1567–1569 
Juan-Pico, P. et al. (2006). Cannabinoid receptors regulate Ca(2+) signals and insulin 
secretion in pancreatic beta-cell. Cell Calcium. No.39, pp. 155–162 
Kadowaki, T. et al. (2006). Adiponectin and adiponectin receptors in insulin resistance, 
diabetes, and the metabolic syndrome. J Clin Invest. No.116, pp. 1784–1792 
Kola, B. et al. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic 
and cardiac effects via AMP-activated protein kinase. J Biol Chem. No.280, pp. 
25196–25201 
Li, C. et al. (2010a). Expression and function of cannabinoid receptors in mouse islets. Islets. 
No.2, pp. 293–302 
Li, C. et al (2010b). Cannabinoid receptors are coupled to stimulation of insulin secretion 
from mouse MIN6 beta-cells. Cell Physiol Biochem. No.26, pp.187–196 
Liu, Y.L. et al. (2005). Effects of the cannabinoid CB1 receptor antagonist SR141716 on 
oxygen consumption and soleus muscle glucose uptake in Lep(ob) ⁄ Lep(ob) mice. 
Int J Obes. No.29, pp. 183–187 
Lutz, B. (2002). Molecular biology of cannabinoid Receptors. Prostaglandins. Leukotrienes and 
Essential Fatty Acids Vol.66, No.2-3, pp. 123-142  
Matias, I. et al. (2006). Regulation, function, and dysregulation of endocannabinoids in 
models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J 
Clin Endocrinol Metab. No.91, pp. 3171–3180 
Matias, I. et al. (2008). Endocannabinoids: Some Like it Fat (and Sweet Too). J 
Neuroendocrinol No.20, pp. 100–109 
Molina-Holgado, E. et al. (2002) Cannabinoids promote oligodendrocyte progenitor 
survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 
kinase/Akt signaling. J. Neurosci. No.22, pp. 9742–9753. 
Müller, T.D. et al. (2007). No evidence for an involvement of variants in the cannabinoid 
receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet 
Metab. Vol.90, No.4, pp. 429-3 
Nakata, M. & Yadam T. (2008). Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) 
oscillation in islet beta-cells via CB1 receptors. Regul Pept. No.145, pp. 49–53 
Ni, Q. et al. (2011). Signaling diversity of PKA achieved via a Ca(2+)-cAMP-PKA oscillatory 
circuit. Nat Chem Biol. No.7, pp. 34–40 
Nogueiras, R. et al. (2008). The endocannabinoid system and the control of glucose 
homeostasis. J Neuroendocrinol. Vol.20, Suppl 1, pp. 147-151 
Onaivi, E.S. et al. (2006). Endocannabinoids: The Brain and Body's Marijuana and Beyond. 
CRC Press, 2005, ISBN: 978- 0-415-30008-7, Boca Raton, FL, USA 
Osei-Hyiaman, D. et al. (2005). Endocannabinoid activation at hepatic CB1 receptors 
stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 
No.115, pp. 1298–1305 
www.intechopen.com
 
The Role of the Endocannabinoid System in the Pathogeny of Type 2 Diabetes 
 
307 
Pagano, C. et al. (2007). The endogenous cannabinoid system stimulates glucose uptake in 
human fat cells via phosphatidylinositol 3-kinase and calcium-dependent 
mechanisms. J Clin Endocrinol Metab. No.92, pp. 4810–4819 
Pagotto, U. et al. (2006). The emerging role of the endocannabinoid system in endocrine 
regulation and energy balance. Endocr Rev. No.27,pp. 73–100 
Patti ME. (2010). Rehashing endocannabinoid antagonists: can we selectively target the 
periphery to safely treat obesity and type 2 diabetes? J Clin Invest. Vol.120, No.8, 
pp. 2646-2648 
Peeters, A. et al. (2007). The G1422A variant of the cannabinoid receptor gene (CNR1) is 
associated with abdominal adiposity in obese men. Endocrine. Vol.31, No.2, pp. 138-
41 
Pertwee, R. (2005). Cannabinoids. Springer, ISBN 3-540-22565-X, Berlin Heidelberg New 
York  
Perwitz, N. et al. (2006). Cannabinoid receptor signaling directly inhibits thermogenesis 
and alters expression of adiponectin and visfatin. Horm Metab Res. No.38, pp. 
356–358 
Piomelli, D. Et al. (1998) Endogenous cannabinoid signaling. Neurobiol Dis No.5, pp. 
462–73 
Russo, P. et al. (2007). Genetic variations at the endocannabinoid type 1 receptor gene 
(CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab. 
Vol.92, No.6, pp. 2382-6 
Sipe, J.C. et al. (2005) Reduced endocannabinoid immune modulation by a common 
cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune 
disorders. J Leukoc Biol. No.78, pp. 231–8 
Sparling, P.B. et al. (2003). Exercise activates the endocannabinoid system. Neuroreport No. 
14, pp. 2209–2211 
Starowicz, K.M. et al. (2008). Endocannabinoid dysregulation in the pancreas and 
adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). No.16, 
pp. 553–565 
Tam, J. et al. (2010). Peripheral CB1 cannabinoid receptor blockade improves 
cardiometabolic risk in mouse models of obesity. J Clin Invest. Vol.120, No.8, pp. 
2953–2966 
Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology 
(ESC) and the European Society for the Study of Diabetes (EASD), (2007). 
Guidelines on diabetes, prediabetes and cardiovascular diseases: executive 
summary. European Heart Journal, No.28, pp. 88-136  
Van Gaal, L. et al. (2008). Efficacy and safety of rimonabant for improvement of multiple 
cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from 
the Rimonabant in Obesity (RIO) program. Diabetes Care. Vol.31, Suppl 2, pp. S229–
S240 
Wilson, R.I. & Nicoll, R.A. (2001). Endogenous cannabinoids mediate retrograde signalling 
at hippocampal synapses. Nature. No.410, pp. 588–92 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
308 
Yan, Z.C. et al. (2007). Exercise reduces adipose tissue via cannabinoid receptor type 1 which 
is regulated by peroxisome proliferatoractivated receptor-delta. Biochem Biophys Res 
Commun. No.354, pp. 427–433 
www.intechopen.com
Role of the Adipocyte in Development of Type 2 Diabetes
Edited by Dr. Colleen Croniger
ISBN 978-953-307-598-3
Hard cover, 372 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Adipocytes are important in the body for maintaining proper energy balance by storing excess energy as
triglycerides. However, efforts of the last decade have identified several molecules that are secreted from
adipocytes, such as leptin, which are involved in signaling between tissues and organs. These adipokines are
important in overall regulation of energy metabolism and can regulate body composition as well as glucose
homeostasis. Excess lipid storage in tissues other than adipose can result in development of diabetes and
nonalcoholic fatty liver disease (NAFLD). In this book we review the role of adipocytes in development of
insulin resistance, type 2 diabetes and NAFLD. Because type 2 diabetes has been suggested to be a disease
of inflammation we included several chapters on the mechanism of inflammation modulating organ injury.
Finally, we conclude with a review on exercise and nutrient regulation for the treatment of type 2 diabetes and
its co-morbidities.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Robert Dinu, Simona Popa and Maria Mota (2011). The Role of the Endocannabinoid System in the
Pathogeny of Type 2 Diabetes, Role of the Adipocyte in Development of Type 2 Diabetes, Dr. Colleen Croniger
(Ed.), ISBN: 978-953-307-598-3, InTech, Available from: http://www.intechopen.com/books/role-of-the-
adipocyte-in-development-of-type-2-diabetes/the-role-of-the-endocannabinoid-system-in-the-pathogeny-of-
type-2-diabetes
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
